Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Joshua M. Hare, MD, FACC, FAHA, a professor of medicine, molecular and cellular pharmacology, and biomedical engineering, director of regenerative medicine, and director of the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami, and co-founder and chief science officer for the stem cell start-up Longeveron, explains the FDA trial for laromestrocel (Lomecel-B) to treat hypoplastic left heart syndrome (HLHS).

First study of its kind to focus on new therapy for hypoplastic left heart syndrome

The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Beta blockers ‘have no effect’ on heart attack patients

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

An attendee at AHA 2024 looking at educational displays on Lp(a) in the Novartis booth. Photo By Dave Fornell

Health systems use AI to target patients who may have elevated Lp(a) levels

"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation. 

Thumbnail

Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?

Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.

radiology trends lungs imaging graphs

FDA clears new trial of first-in-class treatment for pulmonary arterial hypertension

The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024.

Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Chairman of the Board for the Family Heart Foundation, past president of the American Society for Preventive Cardiology, clinical affiliate professor of biomedical science at Florida Atlantic University, and chief medical officer of Flourish Research, explains why testing for familial hypercholesterolemia (FH) and elevated Lipoprotein(a) could be critical to identify more patients with elevated risk of cardiac events, but have their LDL well controlled.

Lipoprotein(a) tests could transform patient care—is it time for universal screening?

"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.

Cardiac amyloidosis ATTR-CM drug promotion at the 2024 American Heart Association meeting.

High cost of cardiac amyloidosis drugs may limit access for low-income patients

"We cannot accept a system where only those with means can benefit from life-changing drugs. We are a wealthy nation that spends trillions on healthcare. We must ensure that income and wealth do not determine access," explained JACC Editor-in-Chief Harlan M. Krumholz, MD.

Displaying 57 - 64 of 427
Design by Adaptive Theme